PT1229047E - Proteinas de fusao de receptores de il-1 utilizadas como antagonistas e processos para a sua producao e utilizacao - Google Patents

Proteinas de fusao de receptores de il-1 utilizadas como antagonistas e processos para a sua producao e utilizacao

Info

Publication number
PT1229047E
PT1229047E PT02007831T PT02007831T PT1229047E PT 1229047 E PT1229047 E PT 1229047E PT 02007831 T PT02007831 T PT 02007831T PT 02007831 T PT02007831 T PT 02007831T PT 1229047 E PT1229047 E PT 1229047E
Authority
PT
Portugal
Prior art keywords
fuseous
antagonists
receptors
utilization
processes
Prior art date
Application number
PT02007831T
Other languages
English (en)
Inventor
George D Yancopoulos
Stahl Neil
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT1229047E publication Critical patent/PT1229047E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
PT02007831T 1998-09-25 1999-09-22 Proteinas de fusao de receptores de il-1 utilizadas como antagonistas e processos para a sua producao e utilizacao PT1229047E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10185898P 1998-09-25 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using

Publications (1)

Publication Number Publication Date
PT1229047E true PT1229047E (pt) 2005-03-31

Family

ID=26798712

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02007831T PT1229047E (pt) 1998-09-25 1999-09-22 Proteinas de fusao de receptores de il-1 utilizadas como antagonistas e processos para a sua producao e utilizacao

Country Status (19)

Country Link
US (2) US6472179B2 (pt)
EP (3) EP1405915A1 (pt)
JP (1) JP3902728B2 (pt)
CN (1) CN100345970C (pt)
AT (2) ATE283365T1 (pt)
AU (1) AU758970C (pt)
BE (1) BE2010C021I2 (pt)
CA (1) CA2345109C (pt)
DE (3) DE69922269T2 (pt)
DK (1) DK1229047T3 (pt)
ES (2) ES2233733T3 (pt)
FR (1) FR10C0025I2 (pt)
HK (2) HK1045847B (pt)
IL (2) IL142103A0 (pt)
NO (2) NO329976B1 (pt)
NZ (1) NZ510720A (pt)
PL (1) PL201246B1 (pt)
PT (1) PT1229047E (pt)
WO (1) WO2000018932A2 (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DK1047781T3 (da) * 1998-01-23 2004-12-06 Immunex Corp IL-18-receptorer
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
ES2549767T3 (es) * 2000-05-26 2015-11-02 Immunex Corporation Uso de anticuerpos de interleuquina-4 y composiciones de los mismos
AU2001274234A1 (en) * 2000-06-16 2001-12-24 Asterion Limited Binding agents: chimeric ligand/receptor proteins
JP5015404B2 (ja) 2000-08-08 2012-08-29 ザイモジェネティクス， インコーポレイテッド 可溶性ｚｃｙｔｏｒ１１サイトカイン受容体
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
WO2003092610A2 (en) * 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
UA90082C2 (ru) 2002-11-15 2010-04-12 Дженмаб А/С Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
AU2004224122A1 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Improved Fc fusion proteins
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
US20050118683A1 (en) * 2003-06-11 2005-06-02 Wood Clive R. Method for producing a polypeptide
SI1648940T1 (sl) * 2003-07-28 2016-08-31 Genentech, Inc. Zmanjševanje izluževanja proteina A med afinitetno kromatografijo proteina A
AU2004270774A1 (en) * 2003-09-05 2005-03-17 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
AU2005219837A1 (en) * 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
AU2005249570B2 (en) 2004-06-04 2011-06-16 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
AU2005266875B2 (en) 2004-07-23 2012-07-26 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
AU2005277357B2 (en) * 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
EP1630232B1 (en) * 2004-08-27 2008-07-02 CONARIS research institute AG Optimized nucleotide sequences encoding sgp130
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
PL2229956T3 (pl) * 2004-09-13 2013-09-30 Genzyme Corp Konstrukty multimeryczne
RU2007117716A (ru) * 2004-10-12 2008-11-20 Ампротеин Корпорейшн (Us) Химерный белок
DE602005022475D1 (de) 2004-10-22 2010-09-02 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
CA2595679A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
ES2539250T3 (es) 2005-07-25 2015-06-29 Emergent Product Development Seattle, Llc Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
WO2007061981A2 (en) 2005-11-21 2007-05-31 Lumera Corporation Surface plasmon resonance spectrometer with an actuator-driven angle scanning mechanism
IN2015DN02553A (pt) * 2005-11-23 2015-09-11 Acceleron Pharma Inc
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
ES2352561T3 (es) 2006-06-30 2011-02-21 Conaris Research Institute Ag Dímeros de sgp 130fc mejorados.
US20100105610A1 (en) * 2006-07-28 2010-04-29 Children's Memorial Hospital Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US20080300185A1 (en) * 2006-10-20 2008-12-04 Catherine Vicary Use of IL-1 antagonists to treat gout and pseudogout
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008093756A1 (ja) * 2007-01-30 2008-08-07 Niigata University 生物学的製剤
WO2008094708A2 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI548647B (zh) 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI667038B (zh) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
ES2449753T3 (es) 2007-03-19 2014-03-21 National Research Council Of Canada Proteínas de fusión que comprenden dos dominios de unión tgf-beta
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
CA2704038A1 (en) * 2007-10-31 2009-05-07 The Scripps Research Institute Combination therapy to treat persistent viral infections
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
WO2010031168A1 (en) * 2008-09-17 2010-03-25 National Research Council Of Canada HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
CN105198997B (zh) 2008-04-11 2018-08-31 阿普拜佛研发有限责任公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
WO2010062383A2 (en) 2008-11-26 2010-06-03 Amgen Inc. Stabilized receptor polypeptides and uses thereof
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
WO2010151426A1 (en) 2009-06-12 2010-12-29 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
AU2012242666A1 (en) 2011-04-15 2013-11-28 Merck Patent Gmbh Anti- IL-1R1 inhibitors for use in cancer
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
SG11201403367YA (en) 2011-12-19 2014-07-30 Amgen Inc Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
KR20220156979A (ko) 2012-11-02 2022-11-28 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
CA2894219C (en) * 2012-12-10 2020-08-11 Vib Vzw Novel interleukin-33 inhibitors
CA2899889A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
MX2015010438A (es) 2013-02-15 2016-05-05 Pharm Cjsc Closed Joint Stock Company R COMPOSICION DE INHIBIDOR DE IL-1ß Y USO DE LA MISMA.
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
DK3170005T3 (da) 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
PT3226888T (pt) 2014-12-01 2021-06-02 Ferring Bv Administração de um inibidor seletivo da trans-sinalização de il-6
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
BR112017011722A2 (pt) 2014-12-03 2018-02-27 Acceleron Pharma Inc antagonistas de activina-actrii e usos para o tratamento de anemia
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
MX2019003445A (es) 2016-09-27 2019-09-26 Epicentrx Inc Proteinas de fusion inmunomoduladoras.
KR20200006528A (ko) * 2017-04-21 2020-01-20 킨드레드 바이오사이언시스, 인코포레이티드 수의학 용도를 위한 il4/il13 수용체 분자
SG11202002826VA (en) 2017-09-27 2020-04-29 Epicentrx Inc Immunomodulatory fusion proteins
KR20200130403A (ko) 2018-03-09 2020-11-18 아게누스 인코포레이티드 항-cd73 항체 및 그의 사용 방법
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN110950965B (zh) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 抗人cd123的嵌合抗原受体及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) * 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
ATE309376T1 (de) * 1990-06-28 2005-11-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
EP0611302B1 (en) * 1991-10-15 2000-03-29 MULLARKEY, Michael F. Receptors for treating late phase inflammatory responses
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ATE172470T1 (de) * 1992-03-09 1998-11-15 Ludwig Inst Cancer Res Für den interleukin-9-rezeptor kodierende nukleinsäuresequenzen bzw. dafür komplementäre nuleinsäuresequenzen
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
CA2160011A1 (en) * 1993-04-06 1994-10-13 Philip D. Greenberg Chimeric cytokine receptors in lymphocytes
WO1995006737A1 (en) * 1993-09-03 1995-03-09 Kenneth Francis Prendergast Glycophorin binding protein (gbp130) fusion compositions
EP0726948B1 (en) * 1993-10-14 2007-02-28 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825A0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
AU3830895A (en) 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU3668897A (en) * 1996-07-17 1998-02-09 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
WO1998008969A1 (en) * 1996-08-26 1998-03-05 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
DK1047781T3 (da) * 1998-01-23 2004-12-06 Immunex Corp IL-18-receptorer

Also Published As

Publication number Publication date
AU758970C (en) 2007-05-03
WO2000018932A2 (en) 2000-04-06
US20020164690A1 (en) 2002-11-07
JP3902728B2 (ja) 2007-04-11
DE69922269D1 (de) 2004-12-30
JP2002525119A (ja) 2002-08-13
EP1405915A1 (en) 2004-04-07
US6472179B2 (en) 2002-10-29
DE122010000023I2 (de) 2012-04-26
DE69932832D1 (de) 2006-09-28
CA2345109C (en) 2012-12-18
DE69922269T2 (de) 2005-12-01
EP1229047B1 (en) 2004-11-24
EP1115876B1 (en) 2006-08-16
DE122010000023I1 (de) 2012-04-26
BE2010C021I2 (pt) 2018-12-04
DK1229047T3 (da) 2005-02-21
PL348529A1 (en) 2002-06-03
CN100345970C (zh) 2007-10-31
HK1035377A1 (en) 2001-11-23
NO20011513L (no) 2001-05-25
CA2345109A1 (en) 2000-04-06
FR10C0025I1 (pt) 2010-05-21
EP1115876A2 (en) 2001-07-18
WO2000018932A9 (en) 2000-08-31
HK1045847B (zh) 2005-03-24
ATE336583T1 (de) 2006-09-15
HK1045847A1 (en) 2002-12-13
NZ510720A (en) 2003-11-28
ES2233733T3 (es) 2005-06-16
PL201246B1 (pl) 2009-03-31
NO20011513D0 (no) 2001-03-23
ATE283365T1 (de) 2004-12-15
NO2011003I1 (no) 2011-05-02
EP1229047A2 (en) 2002-08-07
US20020012962A1 (en) 2002-01-31
AU6499499A (en) 2000-04-17
NO2011003I2 (pt) 2011-04-11
FR10C0025I2 (fr) 2011-04-01
AU758970B2 (en) 2003-04-03
EP1229047A3 (en) 2002-10-02
NO329976B1 (no) 2011-01-31
DE69932832T2 (de) 2007-02-08
WO2000018932A3 (en) 2000-11-02
ES2267300T3 (es) 2007-03-01
IL142103A0 (en) 2002-03-10
IL142103A (en) 2007-07-04
CN1357049A (zh) 2002-07-03

Similar Documents

Publication Publication Date Title
PT1229047E (pt) Proteinas de fusao de receptores de il-1 utilizadas como antagonistas e processos para a sua producao e utilizacao
CY1110675T1 (el) Ανταγωνιστες με βαση υποδοχεα il-1 και μεθοδοι κατασκευης και χρησης
ATE445642T1 (de) Trennung von polypeptiden mit einer racemisierten aminosäure
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
ATE329028T1 (de) Nl3 tie rezeptortyrosinekinase ligandhomologe
TR199902512T2 (xx) Osteoprotegerin ba�lay�c� proteinler ve resept�rler.
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DE69535327D1 (de) Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung
ATE437652T1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
CY1114944T1 (el) Σταθεροποιημενα αλφα ελικοειδη πεπτιδια και χρησεις αυτων
ATE336578T1 (de) Nukleinsäurebindungsproteine
ATE490323T1 (de) Adiponektin-rezeptor und dafür kodierendes gen
DE50108680D1 (de) Multispezifisches reagenz zur selektiven stimulierung von zelloberflächenrezeptoren
CY1109207T1 (el) Διαδικασια εχινοκανδινης
IS6678A (is) Hvarfefni og prófanir fyrir ß-sekretasavirkni
ATE288589T1 (de) Verfahren zur analyse von proteinen
DK1009817T3 (da) RTD-receptor
ES2090357T3 (es) Una proteina de union a colageno asi como su preparacion.
EA200100037A1 (ru) Ангиостатин-связывающий белок
EA199900840A1 (ru) Экспрессия связывающих гербицид полипептидов в растениях для получения их устойчивости к гербицидам
ATE409740T1 (de) Zelllinie und deren verwendung
DE60308176D1 (de) Vorrichtung von peptid- oder proteindarstellung, verfahren zu deren herstellung und deren verwendung